The role of cytokines in cancer

Cytokine and Growth Factor Reviews

Volumn 7, Issue 3, 1996, Pages 279-288

  Oppenheim, Joost J ^a   Fujiwara, Hiromi ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; BONE MORPHOGENETIC PROTEIN; CYTOKINE; ENDOTHELIAL CELL GROWTH FACTOR; GAMMA INTERFERON; GLYCOPROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 8; LYMPHOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; PEPTIDE FRAGMENT; PLASMINOGEN; RECOMBINANT PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR VACCINE; VACCINE; VASCULOTROPIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANGIOGENESIS; ANIMAL; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; CANCER RESEARCH; COLON TUMOR; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KERATINOCYTE; METABOLISM; METASTASIS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; RADIATION EXPOSURE; REVIEW; TH1 CELL; TH2 CELL; TUMOR GROWTH; ULTRAVIOLET RADIATION;

EID: 0030265414     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(96)00025-1     Document Type: Article

References (57)

1. 1. Oppenheim JJ, Rossio JL, Gearing AJH eds. In Clinical Application of Cytokines: Role of Pathogenesis, Diagnosis and Therapy. Oxford University Press, New York, 1993, 1-379.
2. 2. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79, 315-328.
3. 3. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hypermeability, and angiogenesis. Am J Pathol 1995, 146, 1029-1039.
4. 4. Senger DR, Van De Water L, Brown LF, et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Mtg Rev 1993, 12, 303-324.
5. 5. Rak J, Mitsuhashi Y, Erdos V, Huang SN, Filmus J, Kerbel R. Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by mutant c-H-ras oncogene expression. J Cell Biol 1995, 131, 1587-1598.
6. 6. Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995, 55, 4575-4580.
7. 7. Rak JW, St Croix BD, Kerbel RS. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs 1995, 6, 3-18.
8. 8. Strieter RM, Polverini PJ, Kunkel SL, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995, 270, 27348-27357.
9. 9. Strieter RM, Polverini PJ, Arenberg DA, Kunkel SL. The role of CXC chemokines as regulators of angiogenesis. Shock 1995, 4, 155-160.
10. 10. Tosato G, Sgadari C, Taga K, et al. Treatment of experimental Burkitt's lymphomas with normal human B cells immortalized with Ebv. Blood 1994, 83, 776-784.
11. 11. Angiolillo AL, Sgadari C. Taub DD, et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995, 182, 155-162.
12. 12. Taga K, Yamauchi A, Kabashima K, Bloom E, Tosata G. Target-induced death by apoptosis in human lymphokine-activated natural killer cells. Blood 1996, 87, 2411-2418.
13. 13. Ohba Y, Goto Y, Kimura Y, et al. Purification of an angiogenesis inhibitor from culture medium conditioned by a human chondrosarcoma-derived chondrocytic cell line, HCS-2/8. Biochem Biophys Acta 1995, 1245, 1-8.
14. 14. Pandey A, Shao H, Marks RM, Polverini PJ, Dixit VM. The role of B61, the ligand for the Eck receptor tyrosine kinase in TNF-α induced angiogenesis. Science 1995, 268, 567-569.
15. 15. Pandey A, Lindberg R, Dixit V. Cell signalling. Receptor orphans find a family. Curr Biol 1995, 5, 986-989.
16. 16. Pili R, Guo Y, Chang J, Nakamishi H, Martin GR, Passaniti A. Altered angiogenesis underlying age-dependent changes in tumor growth. J Natl Cancer Inst 1994, 86, 1303-1314.
17. 17. Ensoli B, Gendelman R, Markham P, et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein I induction of Kaposi's sarcoma. Nature 1994, 371, 674-680.
18. 18. Hamada J, Cavanaugh P, Miki K, Nicolson G. A paracrine migration-stimulating factor for metastatic tumor cells secreted by mouse hepatic sinusoidal endothelial cells: identification as complement component 3b. Cancer Res 1993, 53, 4418-4423.
19. 19. Wakabayashi H, Cavanaugh P, Nicolson G. Purification and identification of mouse lung microvessel endothelial cell-derived chemoattractant for lung-metastasizing murine large-cell lymphoma cells: identification as mouse monocyte chemotactic protein-1. Cancer Res 1995, 55, 4458-1464.
20. 20. Inoue T, Cavanaugh P, Nicolson G. Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials. J Cell Physiol 1993, 156, 212-217.
21. 21. Yasumoto K, Mukaida N, Harada A, et al. Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice. Cancer Res 1995, 55, 921-927.
22. 22. Lee H, Masuda E, Arai N, Arai K, Yokota T. Definition of cis-regulatory elements of the mouse interleukin-5 gene promoter. J Biol Chem 1995, 270, 17541 17550.
23. 23. Tanaka Y, Takahashi A, Watanabe K, et al. A pivotal role of interleukin-12 in Th1-dependent mouse liver injury. Int. Immunol 1996, 8, 569-576.
24. 24. Nishimura T, Sadata A, Yahagi C, et al. The therapeutic effect of IL-12 or its antagonist in transplantation immunity. Interleukin 12: Cellular and Molecular Immunology of an Important Regulatory Cytokine. Ann New York Acad Sci, New York, (in press).
25. 25. Nishimura T, Watanabe K, Yahata T, et al. The application of IL-12 to cytokine therapy and cytokine gene therapy of tumor. Cancer Chem Ther Pharmacol (in press).
26. 26. Rivas J, Ullrich S. The role of IL-4, IL-10, and TNF-α in the immune suppression induced by ultraviolet radiation. J Leukoc Biol 1994, 56, 769-775.
27. 27. Ullrich SE. Mechanisms involved in the systemic suppression of antigen-presenting cell function by UV irradiation: Keratinocyte-derived IL-10 modulates antigen-presenting cell function of splenic adherent cells. J Immunol 1994, 152, 3410-3416.
28. 28. Schmitt D, Owen-Schaub L, Ullrich S. Effect of IL-12 on immune suppression and suppressor cell induction by ultraviolet radiation. J Immunol 1995, 154, 5114-5120.
29. 29. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-receptor in colon cancer cells with microsatellite instability. Science 1995, 268, 1336-1338.
30. 30. Wang J, Sun L, Myeroff L, et al. Demonstration that mutation of the type II TGF-receptor inactivates its tumor suppressor activity in RER positive colon carcinoma cells. J Biol Chem 1995, 270, 22044 22049.
31. 31. Wang C, Eshleman J, Wilson J, Markowitz S, Kinzler K, Vogelstein B. TGF-β and substrate release are both inducers of apoptosis in a human colon adenoma cell line. Cancer Res 1995, 55, 5101-5105.
32. 32. Parsons R, Myeroff L, Liu B, et al. Microsatellite instability and mutations of the TGF-β type II receptor gene in colorectal cancer. Cancer Res 1995, 55, 5548-5550.
33. 33. Myeroff L, Parsons R, Kim S-J, et al. A TGF-β receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 1995, 55, 5545-5547.
34. 34. Enari M, Hug H, Nagata S. Involvement of an ICE like protease in Fas-mediated apoptosis. Nature 1995, 375, 78-81.
35. 35. Adachi M, Suematsu S, Kondo T, et al. Targeted mutation in the Fas gene causes hyperplasia in the peripheral lymphoid organs and liver. Nature Genetics 1995, 11, 292-300.
36. 36. Ogasawara J, Suda T, Nagata S. Selective apoptosis of CD4 CD8 thymocytes by the anti-Fas antibody. J Exp Med 1995, 181, 485-591.
37. 37. Nagata S, Golstein P. The Fas death factor. Science 1995, 267, 1449-1456.
38. 38. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995, 16, 39-43.
39. 39. Yamamoto N, Zou J-P, Li X-F, et al. Regulatory mechanisms for production of IFN-γ and TNF by anti-tumor T cells or macrophages in the tumor-bearing state. J Immunol 1995, 154, 2281-2290.
40. 40. Mu J, Zou J-P, Yamamoto N. et al. Administration of rIL-12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res 1995, 55, 4404-4408.
41. 41. Fujiwara H, Hamaoka T. The anti-tumor and anti-metastatic effects of interleukin-12. Review. Cancer Chem Ther Pharmacol (in press).
42. 42. Yu W-G. Yamamoto N, Takenaka H, et al. Molecular mechanisms underlying IFN-γ-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12. Internatl Immunol (in press).
43. 43. Wigginton J, Komschlies K, Back T, Franco J, Brunda M, Wiltrout R, Administration of interleukin-12 with pulse interleukin-2 induces rapid and complete regression of established tumor. J Natl Cancer Inst 1996, 88, 38-43.
44. 44. Lin W-C, Yasumura S, Suminami Y, et al. Constitutive production of interleukin 2 by human carcinoma cells, expression of IL2R and tumor cell growth. J Immunol 1995, 155, 4805-4816.
45. 45. Rosenberg S. The development of new cancer therapies based on the molecular identification of cancer regression antigens. Cancer J Sci Am 1995, 1, 90-100.
46. 46. Kawakami Y, Eliyahu S, Delgado C, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994, 91, 6458-6462.
47. 47. Kawakami Y, Eliyahu S, Delgado C, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994, 91, 3515-3519.
48. 48. Robbins P, El-Gamil M, Kawakami Y, Rosenberg S. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res 1994, 54, 3124-3126.
49. 49. Robbins P, El-Gamil M, Li Y, et al. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 1995, 154, 5944-5950.
50. + cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 1994, 91, 9461-9465.
51. 51. Wang R, Robbins P, Kawakami Y, Kang X, Rosenberg S. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31 restricted tumor-infiltrating lymphocytes. J Exp Med 1995, 181, 799-804.
52. 52. Zitvogel L, Mayordomo JI, Tjandrawan T. et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996, 183, 87-97.
53. 53. Golumbek P, Azhari R, Jaffee E, et al. Biodegradable, timed release cytokine depots: A new approach in cancer vaccine design. Cancer Res 1993, 53, 5841-5844.
54. 54. Zhao Z, Jaffee E, Thomas M. Pardoll D, Leong K. Controlled delivery of cytokines for therapeutic cancer vaccination. Proceedings of International Conference on Controlled Release of Bioactive Agents 1995, V22, 51-52.
55. 55. Xiang Z, Ertl H. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 1995, 2, 129-135.
56. 56. Zitvogel L, Tahara H, Robbins P, et al. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol 1995, 155, 1393-1403.
57. 57. Suzuki T, Tahara H, Narula S, Moore K, Robbins P, Lotze M. Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogenic and syngeneic tumors. J. Exp Med 1995, 182, 477-486.